Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
This study has been completed.
Study NCT00842595   Information provided by Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS

First Received on February 11, 2009.   Last Updated on July 12, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
rituximab
navelbine
ifosfamide
Mitoxantrone
Prednisone
Additional drug interventions recognized in this trial
Isophosphamide mustard
Vinorelbine
More general drug interventions related to this trial
Alkylating Agents
Analgesics
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Central Nervous System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services